Abstract
9-Nitrocamptothecin (9-NC) is an efficient antitumor reagent with poor drug-to-lipid entrapment (1:72) in the conventional liposomes formulation. In order to improve the encapsulation and therapeutic efficacy, PEGylated cholesterol (Chol-PEG) was introduced into the 9-NC loaded liposomes formulation by pH gradient encapsulation method. Comparing with conventional composition, 9-NC/lipid molar ratio was increased from 1:72 up to 1:6 in the Chol-PEG based liposomes with uniform size distribution (~120 nm). PEGylated formulation showed obvious lower IC50 value than 9-NC solution (from > 50μmol/L to 5.5 μmol/L on breast cancer 4T1 cells, while from > 50μmol/L to 25.4 μmol/L on hepatoma HepG2 cells) in cytotoxicity measurement. The safety of PEGylated 9-NC liposomes formulation was also illustrated in ex vivo hemolysis test. The enhanced tumor inhibition efficiency of PEGylated 9-NC liposomes was confirmed from tumor-bearing BALB/c mice model using same dosage of 9-NC solution as control (from 28.6% to 70.1% in tumor inhibition). These results suggest that this Chol-PEG based liposome formulation may serve as a promising nanoscale platform for 9-NC controlled delivery.
Keywords: pH-gradient, 9-nitrocamptothecin, PEGylated in vitro, in vivo, cholesterol, liposomes.
Pharmaceutical Nanotechnology
Title:pH-Gradient Incorporation of 9-Nitrocamptothecin in PEGylated Liposomes: Formulation Properties and Efficacy In Vitro and In Vivo
Volume: 1 Issue: 2
Author(s): Shuang Chang, Li Xie, Hong Ding, Yu Nie, Yao Wu, Bin He and Zhongwei Gu
Affiliation:
Keywords: pH-gradient, 9-nitrocamptothecin, PEGylated in vitro, in vivo, cholesterol, liposomes.
Abstract: 9-Nitrocamptothecin (9-NC) is an efficient antitumor reagent with poor drug-to-lipid entrapment (1:72) in the conventional liposomes formulation. In order to improve the encapsulation and therapeutic efficacy, PEGylated cholesterol (Chol-PEG) was introduced into the 9-NC loaded liposomes formulation by pH gradient encapsulation method. Comparing with conventional composition, 9-NC/lipid molar ratio was increased from 1:72 up to 1:6 in the Chol-PEG based liposomes with uniform size distribution (~120 nm). PEGylated formulation showed obvious lower IC50 value than 9-NC solution (from > 50μmol/L to 5.5 μmol/L on breast cancer 4T1 cells, while from > 50μmol/L to 25.4 μmol/L on hepatoma HepG2 cells) in cytotoxicity measurement. The safety of PEGylated 9-NC liposomes formulation was also illustrated in ex vivo hemolysis test. The enhanced tumor inhibition efficiency of PEGylated 9-NC liposomes was confirmed from tumor-bearing BALB/c mice model using same dosage of 9-NC solution as control (from 28.6% to 70.1% in tumor inhibition). These results suggest that this Chol-PEG based liposome formulation may serve as a promising nanoscale platform for 9-NC controlled delivery.
Export Options
About this article
Cite this article as:
Chang Shuang, Xie Li, Ding Hong, Nie Yu, Wu Yao, He Bin and Gu Zhongwei, pH-Gradient Incorporation of 9-Nitrocamptothecin in PEGylated Liposomes: Formulation Properties and Efficacy In Vitro and In Vivo , Pharmaceutical Nanotechnology 2013; 1 (2) . https://dx.doi.org/10.2174/2211738511301020007
DOI https://dx.doi.org/10.2174/2211738511301020007 |
Print ISSN 2211-7385 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-7393 |
Call for Papers in Thematic Issues
Polymeric nanocarriers in drug delivery
Polymeric nanocarriers play a crucial role in drug delivery due to their versatility, and unique properties for targeting and modifying drug release. Their ability to enhance therapeutic outcomes, reduce side effects, and enable the delivery of drugs in a more targeted and controlled manner made them popular in the last ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adjuvant Zoledronic Acid Reduces Disease Recurrence in Breast Cancer: Antitumor Effects on the Seed and the Soil
Current Cancer Therapy Reviews 3-Bromopyruvic Acid, A Hexokinase II Inhibitor, is an Effective Antitumor Agent on the Hepatoma Cells : in vitro and in vivo Findings
Anti-Cancer Agents in Medicinal Chemistry The Human Microbiome Project, Personalized Medicine and the Birth of Pharmacomicrobiomics
Current Pharmacogenomics and Personalized Medicine Drug Carriers in Pharmaceutical Design: Promises and Progress
Current Pharmaceutical Design The Biphasic Expression Pattern of miR-200a and E-cadherin in Epithelial Ovarian Cancer and its Correlation with Clinicopathological Features
Current Pharmaceutical Design Does Religiosity Protect Against Cognitive and Behavioral Decline in Alzheimers Dementia?
Current Alzheimer Research Extracellular Proteases as Targets for Drug Development
Current Protein & Peptide Science Monoclonal Antibodies - Regulatory Challenges
Current Pharmaceutical Biotechnology Bioactive Sterol Derivatives Isolated from the <i>Pleurotus djamor</i> var. Roseus Induced Apoptosis in Cancer Cell Lines
Cardiovascular & Hematological Agents in Medicinal Chemistry Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design New Antimicrobial Frontiers
Mini-Reviews in Medicinal Chemistry Production of High-purity Radium-223 from Legacy Actinium-Beryllium Neutron Sources
Current Radiopharmaceuticals Theranostic Applications of Lutetium-177 in Radionuclide Therapy
Current Radiopharmaceuticals Fibroblast Growth Factors in Development and Cancer: Insights from the Mammary and Prostate Glands
Current Drug Targets Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity
Current Topics in Medicinal Chemistry Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Enzymes To Die For: Exploiting Nucleotide Metabolizing Enzymes for Cancer Gene Therapy
Current Gene Therapy Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma
Current Pharmaceutical Design Treating Cancer and No-Cancer Pain in Older and Oldest Old Patients
Current Pharmaceutical Design Differences in Antiproliferative Activity Between Salinomycin-AZT Conjugates Obtained via ‘Click’ and Esterification Reactions
Medicinal Chemistry